Vorasidenib: What is it and what does it mean for you?

In August 2024, the U.S. Food and Drug Administration approved vorasidenib in patients over the age of 12 with grade 2 astrocytomas or oligodendrogliomas that have a mutation in the isocitrate dehydrogenase (IDH) 1 or 2 genes. In this special webinar, UCSF neuro-oncologist Jennie Taylor, MD, MPH, describes how this drug works, some possible side effects and answers questions from the audience. Thriver Lynton Daniel offers his perspective on taking the medication for over six years.